Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr 2;110(7):1759-66.
doi: 10.1038/bjc.2014.89. Epub 2014 Feb 20.

Serum total hCGβ level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract

Affiliations

Serum total hCGβ level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract

J Douglas et al. Br J Cancer. .

Abstract

Background: Serum total human chorionic gonadotrophin β subunit (hCGβ) level might have prognostic value in urothelial transitional cell carcinoma (TCC) but has not been investigated for independence from other prognostic variables.

Methods: We utilised a clinical database of patients receiving chemotherapy between 2005 and 2011 for urothelial TCC and an independent cohort of radical cystectomy patients for validation purposes. Prognostic variables were tested by univariate Kaplan-Meier analyses and log-rank tests. Statistically significant variables were then assessed by multivariate Cox regression. Total hCGβ level was dichotomised at < vs ≥2 IU l(-1).

Results: A total of 235 chemotherapy patients were eligible. For neoadjuvant chemotherapy, established prognostic factors including low ECOG performance status, normal haemoglobin, lower T stage and suitability for cisplatin-based chemotherapy were associated with favourable survival in univariate analyses. In addition, low hCGβ level was favourable when assessed either before (median survival not reached vs 1.86 years, P=0.001) or on completion of chemotherapy (4.27 vs 0.42 years, P=0.000002). This was confirmed in multivariate analyses and in patients receiving first- and second-line palliative chemotherapy, and in a radical cystectomy validation set.

Conclusions: Serum total hCGβ level is an independent prognostic factor in patients receiving chemotherapy for urothelial TCC in both curative and palliative settings.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram for chemotherapy cohorts used in this study.
Figure 2
Figure 2
Total hCGβ levels before chemotherapy for patients undergoing neoadjuvant, first-line or second-line chemotherapy.
Figure 3
Figure 3
Kaplan–Meier plots to show overall survival according to total hCGβ level in the neoadjuvant (A, B) or first-line (C, D) chemotherapy cohorts either before (A, C), or on completion of (B, D) chemotherapy. Broken line – hCGβ level ⩾2; continuous line – hCGβ level <2.
Figure 4
Figure 4
Kaplan–Meier plot to show overall survival according to total hCGβ level in a radical cystectomy cohort. Broken line – hCGβ level ⩾2; continuous line – hCGβ level <2.

Similar articles

Cited by

References

    1. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005;48 (2:189–199. - PubMed
    1. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48 (2:202–205. - PubMed
    1. Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, Herr H, Higgins G, Boyle MG. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17 (10:3173–3181. - PubMed
    1. Cole LA. Biological functions of hCG and hCG-related molecules. Reprod Biol Endocrinol. 2010;8:102. - PMC - PubMed
    1. Cole LA, Butler S. Hyperglycosylated hCG, hCGbeta and hyperglycosylated hCGbeta: interchangeable cancer promoters. Mol Cell Endocrinol. 2012;349 (2:232–238. - PubMed

Publication types

Substances